APO Research
Talk to an analyst

APO RESEARCH · REPORT

Psychiatric API

Compare research editions
View pricing & licenses

Selected research

Industry Research

Psychiatric API Industry Research Report 2026

22 December 2025130 pages

Choose your research edition.

Industry ResearchPsychiatric API Industry Research Report 2026130 pages · $2,950 USDIndustry Growth & TrendsGlobal Psychiatric API Industry Growth and Trends Forecast to 2032110 pages · $3,450 USDMarket StructureGlobal Psychiatric API Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Psychiatric API Market Outlook and Growth Opportunities 2026202 pages · $4,250 USDMarket Analysis & ForecastGlobal Psychiatric API Market Analysis and Forecast 2026-2032208 pages · $4,950 USD

Market perspective

The global Psychiatric API market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Psychiatric API is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Psychiatric API is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Psychiatric API is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Psychiatric API include Yaopharma, Yangtze River Pharmaceutical, Sichuan Chuanda West China Pharmaceutical, Ren An Pharmaceutical, Eli Lilly, Kanghong Pharmaceutical, Pfizer, Huahai Pharmaceutical and Hengrui Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Psychiatric API market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Psychiatric API Market by Company

Yaopharma

Yangtze River Pharmaceutical

Sichuan Chuanda West China Pharmaceutical

Ren An Pharmaceutical

Eli Lilly

Kanghong Pharmaceutical

Pfizer

Huahai Pharmaceutical

Hengrui Pharmaceuticals

Herui Pharmaceutical

Dongting Pharmaceutical

Brilliant Pharmaceutical

Salutas Pharma

Germany Pharmaceutical

Dr.Reddy's Laboratories

Bora Pharmaceutical

Psychiatric API Segment by Type

Venlafaxine

Paroxetine

Duloxetine

Olanzapine

Others

Psychiatric API Segment by Application

Generalized Anxiety Disorder

Schizophrenia

Fibromyalgia

Major Depressive Disorder

Others

Psychiatric API Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Psychiatric API market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Psychiatric API and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Psychiatric API.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Psychiatric API manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Psychiatric API by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Psychiatric API in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Psychiatric API Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Psychiatric API Sales (k units) of Manufacturers (2021-2026) Table 7. Global Psychiatric API Sales Market Share by Manufacturers (2021-2026) Table 8. Global Psychiatric API Revenue of Manufacturers (2021-2026) Table 9. Global Psychiatric API Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Psychiatric API Average Price (US$/unit) of Manufacturers (2021-2026) Table 11. Global Psychiatric API Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Psychiatric API, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Psychiatric API, Product Type & Application Table 14. Global Psychiatric API Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Psychiatric API by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Yaopharma Company Information Table 19. Yaopharma Business Overview Table 20. Yaopharma Psychiatric API Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 21. Yaopharma Psychiatric API Product Portfolio Table 22. Yaopharma Recent Developments Table 23. Yangtze River Pharmaceutical Company Information Table 24. Yangtze River Pharmaceutical Business Overview Table 25. Yangtze River Pharmaceutical Psychiatric API Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 26. Yangtze River Pharmaceutical Psychiatric API Product Portfolio Table 27. Yangtze River Pharmaceutical Recent Developments Table 28. Sichuan Chuanda West China Pharmaceutical Company Information Table 29. Sichuan Chuanda West China Pharmaceutical Business Overview Table 30. Sichuan Chuanda West China Pharmaceutical Psychiatric API Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 31. Sichuan Chuanda West China Pharmaceutical Psychiatric API Product Portfolio Table 32. Sichuan Chuanda West China Pharmaceutical Recent Developments Table 33. Ren An Pharmaceutical Company Information Table 34. Ren An Pharmaceutical Business Overview Table 35. Ren An Pharmaceutical Psychiatric API Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 36. Ren An Pharmaceutical Psychiatric API Product Portfolio Table 37. Ren An Pharmaceutical Recent Developments Table 38. Eli Lilly Company Information Table 39. Eli Lilly Business Overview Table 40. Eli Lilly Psychiatric API Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 41. Eli Lilly Psychiatric API Product Portfolio Table 42. Eli Lilly Recent Developments Table 43. Kanghong Pharmaceutical Company Information Table 44. Kanghong Pharmaceutical Business Overview Table 45. Kanghong Pharmaceutical Psychiatric API Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 46. Kanghong Pharmaceutical Psychiatric API Product Portfolio Table 47. Kanghong Pharmaceutical Recent Developments Table 48. Pfizer Company Information Table 49. Pfizer Business Overview Table 50. Pfizer Psychiatric API Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 51. Pfizer Psychiatric API Product Portfolio Table 52. Pfizer Recent Developments Table 53. Huahai Pharmaceutical Company Information Table 54. Huahai Pharmaceutical Business Overview Table 55. Huahai Pharmaceutical Psychiatric API Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 56. Huahai Pharmaceutical Psychiatric API Product Portfolio Table 57. Huahai Pharmaceutical Recent Developments Table 58. Hengrui Pharmaceuticals Company Information Table 59. Hengrui Pharmaceuticals Business Overview Table 60. Hengrui Pharmaceuticals Psychiatric API Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 61. Hengrui Pharmaceuticals Psychiatric API Product Portfolio Table 62. Hengrui Pharmaceuticals Recent Developments Table 63. Herui Pharmaceutical Company Information Table 64. Herui Pharmaceutical Business Overview Table 65. Herui Pharmaceutical Psychiatric API Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 66. Herui Pharmaceutical Psychiatric API Product Portfolio Table 67. Herui Pharmaceutical Recent Developments Table 68. Dongting Pharmaceutical Company Information Table 69. Dongting Pharmaceutical Business Overview Table 70. Dongting Pharmaceutical Psychiatric API Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 71. Dongting Pharmaceutical Psychiatric API Product Portfolio Table 72. Dongting Pharmaceutical Recent Developments Table 73. Brilliant Pharmaceutical Company Information Table 74. Brilliant Pharmaceutical Business Overview Table 75. Brilliant Pharmaceutical Psychiatric API Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 76. Brilliant Pharmaceutical Psychiatric API Product Portfolio Table 77. Brilliant Pharmaceutical Recent Developments Table 78. Salutas Pharma Company Information Table 79. Salutas Pharma Business Overview Table 80. Salutas Pharma Psychiatric API Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 81. Salutas Pharma Psychiatric API Product Portfolio Table 82. Salutas Pharma Recent Developments Table 83. Germany Pharmaceutical Company Information Table 84. Germany Pharmaceutical Business Overview Table 85. Germany Pharmaceutical Psychiatric API Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 86. Germany Pharmaceutical Psychiatric API Product Portfolio Table 87. Germany Pharmaceutical Recent Developments Table 88. Dr.Reddy's Laboratories Company Information Table 89. Dr.Reddy's Laboratories Business Overview Table 90. Dr.Reddy's Laboratories Psychiatric API Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 91. Dr.Reddy's Laboratories Psychiatric API Product Portfolio Table 92. Dr.Reddy's Laboratories Recent Developments Table 93. Bora Pharmaceutical Company Information Table 94. Bora Pharmaceutical Business Overview Table 95. Bora Pharmaceutical Psychiatric API Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 96. Bora Pharmaceutical Psychiatric API Product Portfolio Table 97. Bora Pharmaceutical Recent Developments Table 98. Global Psychiatric API Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 99. Global Psychiatric API Sales by Region (2021-2026) & (k units) Table 100. Global Psychiatric API Sales Market Share by Region (2021-2026) Table 101. Global Psychiatric API Sales by Region (2027-2032) & (k units) Table 102. Global Psychiatric API Sales Market Share by Region (2027-2032) Table 103. Global Psychiatric API Revenue by Region (2021-2026) & (US$ Million) Table 104. Global Psychiatric API Revenue Market Share by Region (2021-2026) Table 105. Global Psychiatric API Revenue by Region (2027-2032) & (US$ Million) Table 106. Global Psychiatric API Revenue Market Share by Region (2027-2032) Table 107. North America Psychiatric API Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 108. North America Psychiatric API Sales by Country (2021-2026) & (k units) Table 109. North America Psychiatric API Sales by Country (2027-2032) & (k units) Table 110. North America Psychiatric API Revenue by Country (2021-2026) & (US$ Million) Table 111. North America Psychiatric API Revenue by Country (2027-2032) & (US$ Million) Table 112. Europe Psychiatric API Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 113. Europe Psychiatric API Sales by Country (2021-2026) & (k units) Table 114. Europe Psychiatric API Sales by Country (2027-2032) & (k units) Table 115. Europe Psychiatric API Revenue by Country (2021-2026) & (US$ Million) Table 116. Europe Psychiatric API Revenue by Country (2027-2032) & (US$ Million) Table 117. Asia Pacific Psychiatric API Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 118. Asia Pacific Psychiatric API Sales by Country (2021-2026) & (k units) Table 119. Asia Pacific Psychiatric API Sales by Country (2027-2032) & (k units) Table 120. Asia Pacific Psychiatric API Revenue by Country (2021-2026) & (US$ Million) Table 121. Asia Pacific Psychiatric API Revenue by Country (2027-2032) & (US$ Million) Table 122. South America Psychiatric API Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 123. South America Psychiatric API Sales by Country (2021-2026) & (k units) Table 124. South America Psychiatric API Sales by Country (2027-2032) & (k units) Table 125. South America Psychiatric API Revenue by Country (2021-2026) & (US$ Million) Table 126. South America Psychiatric API Revenue by Country (2027-2032) & (US$ Million) Table 127. Middle East and Africa Psychiatric API Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 128. Middle East and Africa Psychiatric API Sales by Country (2021-2026) & (k units) Table 129. Middle East and Africa Psychiatric API Sales by Country (2027-2032) & (k units) Table 130. Middle East and Africa Psychiatric API Revenue by Country (2021-2026) & (US$ Million) Table 131. Middle East and Africa Psychiatric API Revenue by Country (2027-2032) & (US$ Million) Table 132. Global Psychiatric API Sales by Type (2021-2026) & (k units) Table 133. Global Psychiatric API Sales by Type (2027-2032) & (k units) Table 134. Global Psychiatric API Sales Market Share by Type (2021-2026) Table 135. Global Psychiatric API Sales Market Share by Type (2027-2032) Table 136. Global Psychiatric API Revenue by Type (2021-2026) & (US$ Million) Table 137. Global Psychiatric API Revenue by Type (2027-2032) & (US$ Million) Table 138. Global Psychiatric API Revenue Market Share by Type (2021-2026) Table 139. Global Psychiatric API Revenue Market Share by Type (2027-2032) Table 140. Global Psychiatric API Price by Type (2021-2026) & (US$/unit) Table 141. Global Psychiatric API Price by Type (2027-2032) & (US$/unit) Table 142. Global Psychiatric API Sales by Application (2021-2026) & (k units) Table 143. Global Psychiatric API Sales by Application (2027-2032) & (k units) Table 144. Global Psychiatric API Sales Market Share by Application (2021-2026) Table 145. Global Psychiatric API Sales Market Share by Application (2027-2032) Table 146. Global Psychiatric API Revenue by Application (2021-2026) & (US$ Million) Table 147. Global Psychiatric API Revenue by Application (2027-2032) & (US$ Million) Table 148. Global Psychiatric API Revenue Market Share by Application (2021-2026) Table 149. Global Psychiatric API Revenue Market Share by Application (2027-2032) Table 150. Global Psychiatric API Price by Application (2021-2026) & (US$/unit) Table 151. Global Psychiatric API Price by Application (2027-2032) & (US$/unit) Table 152. Key Raw Materials Table 153. Raw Materials Key Suppliers Table 154. Psychiatric API Distributors List Table 155. Psychiatric API Customers List Table 156. Psychiatric API Industry Trends Table 157. Psychiatric API Industry Drivers Table 158. Psychiatric API Industry Restraints Table 159. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Psychiatric API Product Image Figure 5. Global Psychiatric API Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Psychiatric API Market Size (2021-2032) & (US$ Million) Figure 7. Global Psychiatric API Sales (2021-2032) & (k units) Figure 8. Global Psychiatric API Average Price (US$/unit) & (2021-2032) Figure 9. Venlafaxine Product Image Figure 10. Paroxetine Product Image Figure 11. Duloxetine Product Image Figure 12. Olanzapine Product Image Figure 13. Others Product Image Figure 14. Generalized Anxiety Disorder Product Image Figure 15. Schizophrenia Product Image Figure 16. Fibromyalgia Product Image Figure 17. Major Depressive Disorder Product Image Figure 18. Others Product Image Figure 19. Global Psychiatric API Revenue Share by Manufacturers in 2025 Figure 20. Global Manufacturers of Psychiatric API, Manufacturing Sites & Headquarters Figure 21. Global Top 5 and 10 Psychiatric API Players Market Share by Revenue in 2025 Figure 22. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Global Psychiatric API Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 24. Global Psychiatric API Sales by Region in 2025 Figure 25. Global Psychiatric API Revenue by Region in 2025 Figure 26. North America Psychiatric API Market Size by Country in 2025 Figure 27. North America Psychiatric API Sales Market Share by Country (2021-2032) Figure 28. North America Psychiatric API Revenue Market Share by Country (2021-2032) Figure 29. United States Psychiatric API Revenue Growth Rate (2021-2032) & (US$ Million) Figure 30. Canada Psychiatric API Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. Mexico Psychiatric API Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. Europe Psychiatric API Market Size by Country in 2025 Figure 33. Europe Psychiatric API Sales Market Share by Country (2021-2032) Figure 34. Europe Psychiatric API Revenue Market Share by Country (2021-2032) Figure 35. Germany Psychiatric API Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. France Psychiatric API Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. U.K. Psychiatric API Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Italy Psychiatric API Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Russia Psychiatric API Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Spain Psychiatric API Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Netherlands Psychiatric API Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Switzerland Psychiatric API Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. Sweden Psychiatric API Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. Poland Psychiatric API Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. Asia Pacific Psychiatric API Market Size by Country in 2025 Figure 46. Asia Pacific Psychiatric API Sales Market Share by Country (2021-2032) Figure 47. Asia Pacific Psychiatric API Revenue Market Share by Country (2021-2032) Figure 48. China Psychiatric API Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Japan Psychiatric API Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. South Korea Psychiatric API Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. India Psychiatric API Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Australia Psychiatric API Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. Taiwan Psychiatric API Revenue Growth Rate (2021-2032) & (US$ Million) Figure 54. Southeast Asia Psychiatric API Revenue Growth Rate (2021-2032) & (US$ Million) Figure 55. Southeast Asia Psychiatric API Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. South America Psychiatric API Market Size by Country in 2025 Figure 57. South America Psychiatric API Sales Market Share by Country (2021-2032) Figure 58. South America Psychiatric API Revenue Market Share by Country (2021-2032) Figure 59. Brazil Psychiatric API Revenue Growth Rate (2021-2032) & (US$ Million) Figure 60. Argentina Psychiatric API Revenue Growth Rate (2021-2032) & (US$ Million) Figure 61. Chile Psychiatric API Revenue Growth Rate (2021-2032) & (US$ Million) Figure 62. Middle East and Africa Psychiatric API Market Size by Country in 2025 Figure 63. Middle East and Africa Psychiatric API Sales Market Share by Country (2021-2032) Figure 64. Middle East and Africa Psychiatric API Revenue Market Share by Country (2021-2032) Figure 65. Egypt Psychiatric API Revenue Growth Rate (2021-2032) & (US$ Million) Figure 66. South Africa Psychiatric API Revenue Growth Rate (2021-2032) & (US$ Million) Figure 67. Israel Psychiatric API Revenue Growth Rate (2021-2032) & (US$ Million) Figure 68. Türkiye Psychiatric API Revenue Growth Rate (2021-2032) & (US$ Million) Figure 69. GCC Countries Psychiatric API Revenue Growth Rate (2021-2032) & (US$ Million) Figure 70. Global Psychiatric API Sales Market Share by Type (2021-2032) Figure 71. Global Psychiatric API Revenue Market Share by Type (2021-2032) Figure 72. Global Psychiatric API Price (US$/unit) by Type (2021-2032) Figure 73. Global Psychiatric API Sales Market Share by Application (2021-2032) Figure 74. Global Psychiatric API Revenue Market Share by Application (2021-2032) Figure 75. Global Psychiatric API Price (US$/unit) by Application (2021-2032) Figure 76. Psychiatric API Value Chain Figure 77. Psychiatric API Production Mode & Process Figure 78. Direct Comparison with Distribution Share Figure 79. Distributors Profiles Figure 80. Psychiatric API Industry Opportunities and Challenges

Scope & coverage.

Types
  • Venlafaxine
  • Paroxetine
  • Duloxetine
  • Olanzapine
  • Others
Applications
  • Generalized Anxiety Disorder
  • Schizophrenia
  • Fibromyalgia
  • Major Depressive Disorder
  • Others
Companies covered
  • Yaopharma
  • Yangtze River Pharmaceutical
  • Sichuan Chuanda West China Pharmaceutical
  • Ren An Pharmaceutical
  • Eli Lilly
  • Kanghong Pharmaceutical
  • Pfizer
  • Huahai Pharmaceutical
  • Hengrui Pharmaceuticals
  • Herui Pharmaceutical
  • Dongting Pharmaceutical
  • Brilliant Pharmaceutical
  • Salutas Pharma
  • Germany Pharmaceutical
  • Dr.Reddy's Laboratories
  • Bora Pharmaceutical

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Psychiatric API Market Size (2021-2032)
  4. 2.2.2 Global Psychiatric API Sales (2021-2032)
  5. 2.2.3 Global Psychiatric API Market Average Price (2021-2032)
  6. 2.3 Psychiatric API by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Venlafaxine
  9. 2.3.3 Paroxetine
  10. 2.3.4 Duloxetine
  11. 2.3.5 Olanzapine
  12. 2.3.6 Others
  13. 2.4 Psychiatric API by Application
  14. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  15. 2.4.2 Generalized Anxiety Disorder
  16. 2.4.3 Schizophrenia
  17. 2.4.4 Fibromyalgia
  18. 2.4.5 Major Depressive Disorder
  19. 2.4.6 Others
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Psychiatric API Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Psychiatric API Sales (k units) of Manufacturers (2021-2026)
  3. 3.3 Global Psychiatric API Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Psychiatric API Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Psychiatric API Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Psychiatric API, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Psychiatric API, Product Type & Application
  8. 3.8 Global Manufacturers of Psychiatric API, Established Date
  9. 3.9 Global Psychiatric API Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Yaopharma
  2. 4.1.1 Yaopharma Company Information
  3. 4.1.2 Yaopharma Business Overview
  4. 4.1.3 Yaopharma Psychiatric API Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Yaopharma Psychiatric API Product Portfolio
  6. 4.1.5 Yaopharma Recent Developments
  7. 4.2 Yangtze River Pharmaceutical
  8. 4.2.1 Yangtze River Pharmaceutical Company Information
  9. 4.2.2 Yangtze River Pharmaceutical Business Overview
  10. 4.2.3 Yangtze River Pharmaceutical Psychiatric API Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Yangtze River Pharmaceutical Psychiatric API Product Portfolio
  12. 4.2.5 Yangtze River Pharmaceutical Recent Developments
  13. 4.3 Sichuan Chuanda West China Pharmaceutical
  14. 4.3.1 Sichuan Chuanda West China Pharmaceutical Company Information
  15. 4.3.2 Sichuan Chuanda West China Pharmaceutical Business Overview
  16. 4.3.3 Sichuan Chuanda West China Pharmaceutical Psychiatric API Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Sichuan Chuanda West China Pharmaceutical Psychiatric API Product Portfolio
  18. 4.3.5 Sichuan Chuanda West China Pharmaceutical Recent Developments
  19. 4.4 Ren An Pharmaceutical
  20. 4.4.1 Ren An Pharmaceutical Company Information
  21. 4.4.2 Ren An Pharmaceutical Business Overview
  22. 4.4.3 Ren An Pharmaceutical Psychiatric API Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Ren An Pharmaceutical Psychiatric API Product Portfolio
  24. 4.4.5 Ren An Pharmaceutical Recent Developments
  25. 4.5 Eli Lilly
  26. 4.5.1 Eli Lilly Company Information
  27. 4.5.2 Eli Lilly Business Overview
  28. 4.5.3 Eli Lilly Psychiatric API Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Eli Lilly Psychiatric API Product Portfolio
  30. 4.5.5 Eli Lilly Recent Developments
  31. 4.6 Kanghong Pharmaceutical
  32. 4.6.1 Kanghong Pharmaceutical Company Information
  33. 4.6.2 Kanghong Pharmaceutical Business Overview
  34. 4.6.3 Kanghong Pharmaceutical Psychiatric API Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Kanghong Pharmaceutical Psychiatric API Product Portfolio
  36. 4.6.5 Kanghong Pharmaceutical Recent Developments
  37. 4.7 Pfizer
  38. 4.7.1 Pfizer Company Information
  39. 4.7.2 Pfizer Business Overview
  40. 4.7.3 Pfizer Psychiatric API Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Pfizer Psychiatric API Product Portfolio
  42. 4.7.5 Pfizer Recent Developments
  43. 4.8 Huahai Pharmaceutical
  44. 4.8.1 Huahai Pharmaceutical Company Information
  45. 4.8.2 Huahai Pharmaceutical Business Overview
  46. 4.8.3 Huahai Pharmaceutical Psychiatric API Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Huahai Pharmaceutical Psychiatric API Product Portfolio
  48. 4.8.5 Huahai Pharmaceutical Recent Developments
  49. 4.9 Hengrui Pharmaceuticals
  50. 4.9.1 Hengrui Pharmaceuticals Company Information
  51. 4.9.2 Hengrui Pharmaceuticals Business Overview
  52. 4.9.3 Hengrui Pharmaceuticals Psychiatric API Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Hengrui Pharmaceuticals Psychiatric API Product Portfolio
  54. 4.9.5 Hengrui Pharmaceuticals Recent Developments
  55. 4.10 Herui Pharmaceutical
  56. 4.10.1 Herui Pharmaceutical Company Information
  57. 4.10.2 Herui Pharmaceutical Business Overview
  58. 4.10.3 Herui Pharmaceutical Psychiatric API Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Herui Pharmaceutical Psychiatric API Product Portfolio
  60. 4.10.5 Herui Pharmaceutical Recent Developments
  61. 4.11 Dongting Pharmaceutical
  62. 4.11.1 Dongting Pharmaceutical Company Information
  63. 4.11.2 Dongting Pharmaceutical Business Overview
  64. 4.11.3 Dongting Pharmaceutical Psychiatric API Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Dongting Pharmaceutical Psychiatric API Product Portfolio
  66. 4.11.5 Dongting Pharmaceutical Recent Developments
  67. 4.12 Brilliant Pharmaceutical
  68. 4.12.1 Brilliant Pharmaceutical Company Information
  69. 4.12.2 Brilliant Pharmaceutical Business Overview
  70. 4.12.3 Brilliant Pharmaceutical Psychiatric API Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Brilliant Pharmaceutical Psychiatric API Product Portfolio
  72. 4.12.5 Brilliant Pharmaceutical Recent Developments
  73. 4.13 Salutas Pharma
  74. 4.13.1 Salutas Pharma Company Information
  75. 4.13.2 Salutas Pharma Business Overview
  76. 4.13.3 Salutas Pharma Psychiatric API Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Salutas Pharma Psychiatric API Product Portfolio
  78. 4.13.5 Salutas Pharma Recent Developments
  79. 4.14 Germany Pharmaceutical
  80. 4.14.1 Germany Pharmaceutical Company Information
  81. 4.14.2 Germany Pharmaceutical Business Overview
  82. 4.14.3 Germany Pharmaceutical Psychiatric API Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 Germany Pharmaceutical Psychiatric API Product Portfolio
  84. 4.14.5 Germany Pharmaceutical Recent Developments
  85. 4.15 Dr.Reddy's Laboratories
  86. 4.15.1 Dr.Reddy's Laboratories Company Information
  87. 4.15.2 Dr.Reddy's Laboratories Business Overview
  88. 4.15.3 Dr.Reddy's Laboratories Psychiatric API Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 Dr.Reddy's Laboratories Psychiatric API Product Portfolio
  90. 4.15.5 Dr.Reddy's Laboratories Recent Developments
  91. 4.16 Bora Pharmaceutical
  92. 4.16.1 Bora Pharmaceutical Company Information
  93. 4.16.2 Bora Pharmaceutical Business Overview
  94. 4.16.3 Bora Pharmaceutical Psychiatric API Sales, Revenue and Gross Margin (2021-2026)
  95. 4.16.4 Bora Pharmaceutical Psychiatric API Product Portfolio
  96. 4.16.5 Bora Pharmaceutical Recent Developments
5 Global Psychiatric API Market Scenario by Region
  1. 5.1 Global Psychiatric API Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Psychiatric API Sales by Region: 2021-2032
  3. 5.2.1 Global Psychiatric API Sales by Region: 2021-2026
  4. 5.2.2 Global Psychiatric API Sales by Region: 2027-2032
  5. 5.3 Global Psychiatric API Revenue by Region: 2021-2032
  6. 5.3.1 Global Psychiatric API Revenue by Region: 2021-2026
  7. 5.3.2 Global Psychiatric API Revenue by Region: 2027-2032
  8. 5.4 North America Psychiatric API Market Facts & Figures by Country
  9. 5.4.1 North America Psychiatric API Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Psychiatric API Sales by Country (2021-2032)
  11. 5.4.3 North America Psychiatric API Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Psychiatric API Market Facts & Figures by Country
  16. 5.5.1 Europe Psychiatric API Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Psychiatric API Sales by Country (2021-2032)
  18. 5.5.3 Europe Psychiatric API Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Psychiatric API Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Psychiatric API Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Psychiatric API Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Psychiatric API Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Psychiatric API Market Facts & Figures by Country
  41. 5.7.1 South America Psychiatric API Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Psychiatric API Sales by Country (2021-2032)
  43. 5.7.3 South America Psychiatric API Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa Psychiatric API Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa Psychiatric API Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa Psychiatric API Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa Psychiatric API Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Psychiatric API Sales by Type (2021-2032)
  2. 6.1.1 Global Psychiatric API Sales by Type (2021-2032) & (k units)
  3. 6.1.2 Global Psychiatric API Sales Market Share by Type (2021-2032)
  4. 6.2 Global Psychiatric API Revenue by Type (2021-2032)
  5. 6.2.1 Global Psychiatric API Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Psychiatric API Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Psychiatric API Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Psychiatric API Sales by Application (2021-2032)
  2. 7.1.1 Global Psychiatric API Sales by Application (2021-2032) & (k units)
  3. 7.1.2 Global Psychiatric API Sales Market Share by Application (2021-2032)
  4. 7.2 Global Psychiatric API Revenue by Application (2021-2032)
  5. 7.2.1 Global Psychiatric API Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Psychiatric API Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Psychiatric API Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Psychiatric API Value Chain Analysis
  2. 8.1.1 Psychiatric API Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Psychiatric API Production Mode & Process
  5. 8.2 Psychiatric API Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Psychiatric API Distributors
  8. 8.2.3 Psychiatric API Customers
9 Global Psychiatric API Analyzing Market Dynamics
  1. 9.1 Psychiatric API Industry Trends
  2. 9.2 Psychiatric API Industry Drivers
  3. 9.3 Psychiatric API Industry Opportunities and Challenges
  4. 9.4 Psychiatric API Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst